China-made PD-1 inhibitors just can’t get a clean pass through the FDA.  | China-made PD-1 inhibitors continue to struggle at ...

Seven months after Amgen’s chief medical officer referred to trial results for the company's investigational lung cancer ...

After Moderna last year suffered a loss in its heated patent fight against Pfizer and BioNTech, the mRNA drugmaker can now ...

Following a controversy over Covis’ preterm birth drug Makena in the U.S. last year, the European Medicines Agency (EMA) is ...

The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. | The momentum the ...

Right on the heels of a similar move by Johnson & Johnson, GSK is offloading the rest of its stake in the consumer healthcare ...

AbbVie’s newest psoriasis awareness-raising campaign is taking the skin condition out of the spotlight. | AbbVie’s newest ...

As it prepares to push its kidney care portfolio out of the nest, Baxter International isn’t branching out too widely with ...

This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and ...

The FDA has broadened the use of Bristol Myers Squibb’s CAR-T therapy Breyanzi to another type of blood cancer. | The FDA has ...

After admitting to the crime four years ago, a former Sandoz executive will avoid hard time for his part in a generic drug ...

The company formerly known as First Wave BioPharma has found itself on dry land with a decidedly non-aquatic new moniker. The ...